Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized double-blind phase IIb study of JNJ-73763989 and/or JNJ-56136379 in chronic hepatitis B virus infection
CTR20200031Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tomligisiran in Chronic Hepatitis B (CHB), sponsored by Janssen Pharmaceutical. Started Feb 2020; status: completed.
02
Drugs
tomligisiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20200031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200031.